

Special Issue

Anticancer Drugs in Immunotherapy: Molecular Mechanisms, Translational Insights, and Clinical Applications

Message from the Guest Editor

The advent of immune checkpoint inhibitors, adoptive cell therapies, and immune adjuvants has revolutionized cancer therapy. However, the efficacy of immunotherapy is limited by resistance, immune evasion, and tumor microenvironmental barriers. Anticancer drugs, including chemotherapeutics, targeted agents, and novel small molecules, are now being integrated into immunotherapy regimens to enhance antitumor immunity and overcome resistance.

This Special Issue aims to explore the synergistic mechanisms by which anticancer drugs modulate the immune landscape, influence immunogenic cell death, or augment checkpoint blockade.

Topics of interest include (but are not limited to) the following:

- Mechanisms of immunogenic cell death induced by chemotherapy or radiation;
- Small molecules and targeted drugs enhancing T-cell priming or APC function;
- Drug-induced modulation of tumor immune microenvironment;
- Epigenetic drugs and immune reprogramming;
- Overcoming resistance to checkpoint blockade with drug combinations;
- Immunotherapy sensitization in “cold” tumors via conventional agents;
- Clinical trials involving anticancer drugs combined with immunotherapy.

Guest Editor

Dr. Bashir Lawal

Department of Pathology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA

Deadline for manuscript submissions

28 February 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/248991

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).